PE
MDGL icon

Point72 Europe’s Madrigal Pharmaceuticals MDGL Stock Holding History

Point72 Europe’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$68.1K Buy
+148
New +$55.2K ﹤0.01% 328
2018
Q2 		– Sell
-8,900
Closed -$1.04M – 26
2018
Q1 		$1.04M Buy
+8,900
New +$1.1M 0.82% 20

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Point72 Europe's MDGL Position: Q3 2025 in Review

Point72 Europe opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2025: 148 shares worth $68.1K. The stake represents ﹤0.01% of the portfolio and ranks #328 among its holdings. This is a return to the name: Point72 Europe previously reported a position in MDGL as recently as Q1 2018.

Point72 Europe first reported a position in MDGL in Q1 2018 and has held it in 2 quarters since. The position peaked at $1.04M in Q1 2018. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Point72 Europe held 148 shares of Madrigal Pharmaceuticals worth $68.1K as of Q3 2025.
  • Madrigal Pharmaceuticals was a new Point72 Europe position in Q3 2025.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #328 holding.
  • Point72 Europe first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 2 quarters since.
  • Point72 Europe's Madrigal Pharmaceuticals position peaked at $1.04M in Q1 2018.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.